• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Gut microbiota-an important contributor to liver diseases].[肠道微生物群——肝脏疾病的重要促成因素]
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Apr 30;40(4):595-600. doi: 10.12122/j.issn.1673-4254.2020.04.23.
2
Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.靶向肠道微生物群的慢性肝脏疾病管理方法。
Front Cell Infect Microbiol. 2022 Apr 4;12:774335. doi: 10.3389/fcimb.2022.774335. eCollection 2022.
3
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群:非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
4
Gut microbiome and liver diseases.肠道微生物组与肝脏疾病。
Gut. 2016 Dec;65(12):2035-2044. doi: 10.1136/gutjnl-2016-312729. Epub 2016 Oct 8.
5
[Gut-liver axis: How intestinal bacteria affect the liver].肠-肝轴:肠道细菌如何影响肝脏
MMW Fortschr Med. 2018 Nov;160(Suppl 5):11-15. doi: 10.1007/s15006-018-1051-6. Epub 2018 Oct 26.
6
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.肠-肝轴、肝硬化和门静脉高压:先有鸡还是先有蛋。
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
7
Gut microbiota and host metabolism in liver cirrhosis.肝硬化中的肠道微生物群与宿主代谢
World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597.
8
A narrative review of relationship between gut microbiota and neuropsychiatric disorders: mechanisms and clinical application of probiotics and prebiotics.肠道微生物群与神经精神疾病关系的叙述性综述:益生菌和益生元的作用机制及临床应用
Ann Palliat Med. 2021 Feb;10(2):2304-2313. doi: 10.21037/apm-20-1365. Epub 2021 Jan 28.
9
A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.肝脏与肠道微生物的故事:肠道菌群如何影响肝脏疾病?文献综述。
Am J Physiol Gastrointest Liver Physiol. 2020 May 1;318(5):G889-G906. doi: 10.1152/ajpgi.00161.2019. Epub 2020 Mar 9.
10
The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.益生菌在非酒精性脂肪性肝病中的作用:治疗策略的新视角。
Nutrients. 2019 Nov 4;11(11):2642. doi: 10.3390/nu11112642.

引用本文的文献

1
839 ameliorates anti-tuberculosis drugs-induced liver injury by suppressing inflammation and regulating gut microbiota in mice.839通过抑制炎症和调节小鼠肠道微生物群来改善抗结核药物引起的肝损伤。
Front Med (Lausanne). 2025 Apr 17;12:1538528. doi: 10.3389/fmed.2025.1538528. eCollection 2025.
2
Capsaicin Modulates Hepatic and Intestinal Inflammation and Oxidative Stress by Regulating the Colon Microbiota.辣椒素通过调节结肠微生物群来调节肝脏和肠道炎症及氧化应激。
Antioxidants (Basel). 2024 Aug 2;13(8):942. doi: 10.3390/antiox13080942.
3
[Lithocholic acid decreases mRNA stability of nuclear receptor PPAR by upregulating miR-21 expression in hepatoma HepG2 cells].[石胆酸通过上调肝癌HepG2细胞中miR-21的表达降低核受体PPAR的mRNA稳定性]
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Dec 20;43(12):2086-2094. doi: 10.12122/j.issn.1673-4254.2023.12.13.
4
Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis.婴儿胆汁淤积症患者的肠道微生物群和代谢物谱的变化。
BMC Microbiol. 2023 Nov 18;23(1):357. doi: 10.1186/s12866-023-03115-1.
5
Study on the Hepatoprotective Effect Mechanism of Polysaccharides from Charred on the Layer Chickens Based on the Detection of the Intestinal Floras and Short-Chain Fatty Acids of Cecal Contents and Association Analysis.基于盲肠内容物肠道菌群及短链脂肪酸检测与关联分析的焦糊层多糖对蛋鸡的保肝作用机制研究
Vet Sci. 2023 Mar 15;10(3):224. doi: 10.3390/vetsci10030224.
6
Proteomics analysis reveals novel insights into the mechanism of hepatotoxicity induced by multiglycoside in mice.蛋白质组学分析揭示了多糖苷诱导小鼠肝毒性机制的新见解。
Front Pharmacol. 2022 Nov 17;13:1032741. doi: 10.3389/fphar.2022.1032741. eCollection 2022.
7
Magnesium Isoglycyrrhizinate Attenuates Anti-Tuberculosis Drug-Induced Liver Injury by Enhancing Intestinal Barrier Function and Inhibiting the LPS/TLRs/NF-κB Signaling Pathway in Mice.异甘草酸镁通过增强肠道屏障功能和抑制小鼠LPS/TLRs/NF-κB信号通路减轻抗结核药物所致肝损伤
Pharmaceuticals (Basel). 2022 Sep 9;15(9):1130. doi: 10.3390/ph15091130.
8
Effects of Previous Kasai Surgery on Gut Microbiota and Bile Acid in Biliary Atresia With End-Stage Liver Disease.既往葛西手术对终末期肝病型胆道闭锁患儿肠道微生物群和胆汁酸的影响
Front Med (Lausanne). 2021 Sep 27;8:704328. doi: 10.3389/fmed.2021.704328. eCollection 2021.

本文引用的文献

1
Alterations of gut microbiome in autoimmune hepatitis.自身免疫性肝炎中肠道微生物组的改变。
Gut. 2020 Mar;69(3):569-577. doi: 10.1136/gutjnl-2018-317836. Epub 2019 Jun 14.
2
Role of Gut Microbiota in Hepatocarcinogenesis.肠道微生物群在肝癌发生中的作用。
Microorganisms. 2019 May 5;7(5):121. doi: 10.3390/microorganisms7050121.
3
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.肠-肝轴、肠道微生物群及其在肝脏疾病治疗中的调控:文献综述。
Int J Mol Sci. 2019 Jan 17;20(2):395. doi: 10.3390/ijms20020395.
4
Alcohol, liver disease and the gut microbiota.酒精、肝病与肠道微生物组。
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):235-246. doi: 10.1038/s41575-018-0099-1.
5
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.肠道微生物群与胆汁酸失调在非酒精性脂肪性肝病发病机制中的相互作用及益生菌的潜在治疗意义。
J Cell Biochem. 2019 Mar;120(3):2713-2720. doi: 10.1002/jcb.27635. Epub 2018 Nov 15.
6
Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels.丁酸盐通过改善肠道屏障功能、减轻炎症和降低内毒素水平,保护小鼠免受蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝炎的影响。
Front Microbiol. 2018 Aug 21;9:1967. doi: 10.3389/fmicb.2018.01967. eCollection 2018.
7
The gut-liver axis and the intersection with the microbiome.肠-肝轴与微生物组的交汇。
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411. doi: 10.1038/s41575-018-0011-z.
8
Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.靶向肠道微生物群治疗肝细胞癌:益生菌作为一种新型疗法。
Hepatobiliary Surg Nutr. 2018 Feb;7(1):11-20. doi: 10.21037/hbsn.2017.12.07.
9
Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice.肠道微生物群介导了对乙酰氨基酚诱导的小鼠急性肝损伤的昼夜变化。
J Hepatol. 2018 Jul;69(1):51-59. doi: 10.1016/j.jhep.2018.02.024. Epub 2018 Mar 8.
10
Commensal Lactobacillus Controls Immune Tolerance during Acute Liver Injury in Mice.共生乳杆菌在小鼠急性肝损伤期间控制免疫耐受。
Cell Rep. 2017 Oct 31;21(5):1215-1226. doi: 10.1016/j.celrep.2017.10.022.

[肠道微生物群——肝脏疾病的重要促成因素]

[Gut microbiota-an important contributor to liver diseases].

作者信息

Wang Fangzhao, Cui Qianru, Zeng Yunong, Chen Peng

机构信息

Department of Pathophysiology, College of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2020 Apr 30;40(4):595-600. doi: 10.12122/j.issn.1673-4254.2020.04.23.

DOI:10.12122/j.issn.1673-4254.2020.04.23
PMID:32895142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7225115/
Abstract

Gut microbiota constitute a complicated but manifold ecosystem, in which specific symbiotic relationships are formed among various bacteria. To maintain a steady state, the gastrointestinal tract and the liver form a close anatomical and functional two-way, interconnected network through the portal circulation. "Gut-liver axis" plays a key role in the pathogenesis of liver diseases. Accumulating evidence indicates that gut microbiota can influence the liver pathophysiology directly or indirectly via a variety of signal pathways. In a pathological state where an ecological imbalance occurs at the compositional and functional levels, gut microbes would interact with the host immune system and other type of cells to cause liver steatosis, inflammation and fibrosis, which in turn give rise to the development of such liver diseases as alcoholic liver disease, nonalcoholic fatty liver disease, primary sclerosing cholangitis, and acute liver failure, to name a few. Studies have shown that microorganisms, such as prebiotics and probiotics, can improve the prognosis of certain diseases, which open a new era of treating liver diseases with bacteria. There are many unknowns and hidden values in the gut microbiome. To explore the pathophysiological mechanism of various complex diseases and develop scientific and effective clinical treatment strategies, efforts should be made to obtain insights into how certain intestinal microbiota participates in the occurrence and progression of liver diseases. As the connection between gut microbiota and liver diseases at both the acute and chronic phases was not elaborated in previously published review articles, herein we discuss the association between gut microbiota and both acute and chronic liver injury. The anatomical structure of the liver enables it to form a close network with the gut microbiota, which is an important mediator in the regulation of the hepatic physiological and pathological functions.

摘要

肠道微生物群构成了一个复杂但多样的生态系统,其中各种细菌之间形成了特定的共生关系。为了维持稳态,胃肠道和肝脏通过门静脉循环形成了一个紧密的解剖学和功能上的双向互联网络。“肠-肝轴”在肝脏疾病的发病机制中起关键作用。越来越多的证据表明,肠道微生物群可通过多种信号通路直接或间接影响肝脏病理生理学。在组成和功能水平出现生态失衡的病理状态下,肠道微生物会与宿主免疫系统及其他类型的细胞相互作用,导致肝脏脂肪变性、炎症和纤维化,进而引发诸如酒精性肝病、非酒精性脂肪性肝病、原发性硬化性胆管炎和急性肝衰竭等肝脏疾病。研究表明,益生元和益生菌等微生物可改善某些疾病的预后,这开启了用细菌治疗肝脏疾病的新时代。肠道微生物组存在许多未知和潜在价值。为了探索各种复杂疾病的病理生理机制并制定科学有效的临床治疗策略,应努力深入了解某些肠道微生物群如何参与肝脏疾病的发生和发展。由于此前发表的综述文章未阐述肠道微生物群与急慢性肝病阶段的联系,因此我们在此讨论肠道微生物群与急慢性肝损伤之间的关联。肝脏的解剖结构使其能够与肠道微生物群形成紧密网络,而肠道微生物群是调节肝脏生理和病理功能的重要介质。